HCA Healthcare, Inc. (HCA) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $395.33 (+1.40%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 28, 2026 | Andrew Mok | Barclays | $551.00 | +39.4% |
| Jan 7, 2026 | Stephen Baxter | Wells Fargo | $452.00 | +14.3% |
| Oct 27, 2025 | Raj Kumar | Stephens | $500.00 | +26.5% |
| Oct 27, 2025 | Ben Hendrix | RBC Capital | $482.00 | +21.9% |
| Oct 27, 2025 | Scott Fidel | Goldman Sachs | $520.00 | +31.5% |
| Oct 27, 2025 | Sarah James | Raymond James | $525.00 | +32.8% |
| Jul 28, 2025 | Ben Hendrix | RBC Capital | $401.00 | +1.4% |
| Jun 9, 2025 | Craig Hettenbach | Morgan Stanley | $410.00 | +3.7% |
| Jun 2, 2025 | Andrew Mok | Barclays | $416.00 | +5.2% |
| Jan 7, 2025 | Matthew Gillmor | KeyBanc | $370.00 | -6.4% |
| Oct 28, 2024 | Michael Wiederhorn | Oppenheimer | $400.00 | +1.2% |
| Oct 28, 2024 | Matthew Gillmor | KeyBanc | $420.00 | +6.2% |
| Oct 28, 2024 | Ann Hynes | Mizuho Securities | $425.00 | +7.5% |
| Oct 10, 2024 | Matthew Gillmor | KeyBanc | $475.00 | +20.2% |
| Oct 1, 2024 | Pito Chickering | Deutsche Bank | $441.00 | +11.6% |
| Aug 19, 2024 | David MacDonald | Truist Financial | $430.00 | +8.8% |
| Jun 28, 2024 | Pito Chickering | Deutsche Bank | $375.00 | -5.1% |
| Jun 6, 2024 | Brian Tanquilut | Jefferies | $390.00 | -1.3% |
| Apr 29, 2024 | Ben Hendrix | RBC Capital | $329.00 | -16.8% |
| Apr 29, 2024 | Michael Wiederhorn | Oppenheimer | $345.00 | -12.7% |
Top Analysts Covering HCA
HCA vs Sector & Market
| Metric | HCA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.19 | 2.24 | 2.40 |
| Analyst Count | 26 | 8 | 19 |
| Target Upside | +29.8% | +11475.0% | +17.1% |
| P/E Ratio | 13.59 | 3.90 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $77.15B | $78.60B | $80.10B | 18 |
| 2027-03-31 | $19.80B | $20.08B | $20.31B | 11 |
| 2027-06-30 | $19.96B | $20.24B | $20.47B | 7 |
| 2027-09-30 | $20.43B | $20.72B | $20.96B | 8 |
| 2027-12-31 | $20.93B | $21.22B | $21.47B | 7 |
| 2028-03-31 | $21.12B | $21.42B | $21.67B | 6 |
| 2028-06-30 | $20.78B | $21.07B | $21.31B | 6 |
| 2028-09-30 | $21.32B | $21.62B | $21.87B | 11 |
| 2028-12-31 | $22.12B | $22.43B | $22.69B | 6 |
| 2029-12-31 | $91.00B | $92.67B | $94.92B | 5 |
| 2030-12-31 | $98.60B | $100.42B | $102.86B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $29.18 | $30.26 | $31.40 | 16 |
| 2027-03-31 | $7.80 | $7.94 | $8.06 | 10 |
| 2027-06-30 | $8.01 | $8.16 | $8.28 | 6 |
| 2027-09-30 | $7.78 | $7.93 | $8.05 | 7 |
| 2027-12-31 | $9.17 | $9.33 | $9.48 | 6 |
| 2028-03-31 | $8.96 | $9.12 | $9.26 | 7 |
| 2028-06-30 | $8.44 | $8.59 | $8.72 | 7 |
| 2028-09-30 | $7.90 | $8.04 | $8.16 | 12 |
| 2028-12-31 | $10.46 | $10.65 | $10.81 | 7 |
| 2029-12-31 | $41.58 | $42.58 | $43.92 | 6 |
| 2030-12-31 | $48.20 | $49.36 | $50.92 | 6 |
Frequently Asked Questions
What is the analyst consensus for HCA?
The consensus among 26 analysts covering HCA Healthcare, Inc. (HCA) is Buy with an average price target of $523.92.
What is the highest price target for HCA?
The highest price target for HCA is $551.00, set by Andrew Mok at Barclays on 2026-01-28.
What is the lowest price target for HCA?
The lowest price target for HCA is $224.00, set by Justin Lake at Wolfe Research on 2021-06-21.
How many analysts cover HCA?
26 analysts have issued ratings for HCA Healthcare, Inc. in the past 12 months.
Is HCA a buy or sell right now?
Based on 26 analyst ratings, HCA has a consensus rating of Buy (2.19/5) with a +29.8% upside to the consensus target of $523.92.
What are the earnings estimates for HCA?
Analysts estimate HCA will report EPS of $30.26 for the period ending 2026-12-31, with revenue estimated at $78.60B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.